Page 1080 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 3

61. Presterl E, Parschalk B, Bauer E, et al. Invasive fungal infections 77. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-
and (1,3)-beta-D-glucan serum concentrations in long-term controlled trial of fluconazole to prevent candidal infections in
intensive care patients. Internat J Infect Dis. 2009;13:707-712. critically ill surgical patients. Ann Surg. 2001;233:542-548.
62. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter 78. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis
clinical evaluation of the (1-->3) beta-D-glucan assay as an prevents intra-abdominal candidiasis in high-risk surgical
aid to diagnosis of fungal infections in humans. Clin Infect Dis. patients. Crit Care Med. 1999;27:1066-1072.
2005;41:654-659. 79. Senn L, Eggimann P, Ksontini R, et al. Caspofungin for pre-
63. Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the vention of intra-abdominal candidiasis in high-risk surgical
serum (1→3)-beta-D-glucan assay for the diagnosis of invasive patients. Intensive Care Med. 2009;35:903-908.
fungal infections—a study based on autopsy cases from 6 years. 80. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal
Clin Infect Dis. 2008;46:1864-1870.
agents for preventing fungal infections in non-neutropenic
64. Ahmad S, Khan Z, Mustafa AS, et al. Seminested PCR for diag- critically ill and surgical patients: systematic review and meta-
nosis of candidemia: comparison with culture, antigen detec- analysis of randomized clinical trials. J Antimicrobial Chemother.
tion, and biochemical methods for species identification. J Clin 2006;57:628-638.
Microbiol. 2002;40:2483-2489.
81. Vardakas KZ, Samonis G, Michalopoulos A, Soteriades ES,
65. McMullan R, Metwally L, Coyle PV, et al. A prospective clini- Falagas ME. Antifungal prophylaxis with azoles in high-risk, sur-
cal trial of a real-time polymerase chain reaction assay for the gical intensive care unit patients: a meta-analysis of randomized,
diagnosis of candidemia in nonneutropenic, critically ill adults. placebo-controlled trials. Crit Care Med. 2006;34:1216-1224.
Clin Infect Dis. 2008;46:890-896.
82. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice
66. Hollenbach E. Invasive candidiasis in the ICU: evidence based guidelines for the management of candidiasis: 2009 update
and on the edge of evidence. Mycoses. 2008;51:25-45. by the Infectious Diseases Society of America. Clin Infect Dis.
67. Eggimann P, Garbino J, Pittet D. Management of Candida 2009;48:503-535.
species infections in critically ill patients. Lancet Infect Dis. 83. Schuster MG, Edwards JE Jr, Sobel JD, et al. Empirical flucon-
2003;3:772-785. azole versus placebo for intensive care unit patients: a random-
68. Leon C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring ized trial. Ann Intern Med. 2008;149:83-90.
system (“Candida score”) for early antifungal treatment in non- 84. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial com-
neutropenic critically ill patients with Candida colonization. paring fluconazole with amphotericin B for the treatment of
Crit Care Med. 2006;34:730-737.
candidemia in patients without neutropenia. N Engl J Med.
69. Leon C, Ruiz-Santana S, Saavedra P, et al. Usefulness of the 1994;331:1325-1330.
“Candida score” for discriminating between Candida coloni- 85. Phillips P, Shafran S, Garber G, et al. Multicenter randomized
zation and invasive candidiasis in non-neutropenic critically trial of fluconazole versus amphotericin B for treatment of can-
ill patients: a prospective multicenter study. Crit Care Med. didemia in non-neutropenic patients. Eur J Clin Microbiol Infect
2009;37:1624-1633.
Dis. 1997;16:337-345.
70. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying
patients at increased risk for candidal infections in the surgical 86. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and
intensive care unit: approach to developing practical criteria blinded multicenter trial of high-dose fluconazole plus placebo
for systematic use in antifungal prophylaxis trials. Med Mycol. versus fluconazole plus amphotericin B as therapy for candi-
2005;43:235-243. demia and its consequences in nonneutropenic subjects. Clin
Infect Dis. 2003;36:1221-1228.
71. Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retro-
spective development and validation of a clinical prediction rule 87. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspo-
for nosocomial invasive candidiasis in the intensive care setting. fungin and amphotericin B for invasive candidiasis. N Engl J
Eur J Clin Microbiol Infect Dis. 2007;26:271-276. Med. 2002;347:2020-2029.
72. Piarroux R, Grenouillet F, Balvay P, et al. Assessment of pre- 88. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin
emptive treatment to prevent severe candidiasis in critically ill versus liposomal amphotericin B for candidaemia and invasive
surgical patients. Crit Care Med. 2004;32:2443-2449. candidosis: a phase III randomised double-blind trial. Lancet.
73. Smith JA, Kauffman CA. Recognition and prevention of noso- 2007;369:1519-1527.
comial invasive fungal infections in the intensive care unit. Crit 89. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin
Care Med. 2010;38(suppl):S380-S387. versus fluconazole for invasive candidiasis. N Engl J Med.
2007;356:2472-2482.
74. Garbino J, Lew DP, Romand J-A, et al. Prevention of severe
Candida infections in nonneutropenic, high-risk, critically 90. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus
ill patients: a randomized, double-blind, placebo-controlled caspofungin for treatment of candidemia and other forms of
trial in patients treated by selective digestive decontamination. invasive candidiasis. Clin Infect Dis. 2007;45:883-893.
Intensive Care Med. 2002;28:1708-1717. 91. Betts RF, Nucci M, Talwar D, et al. A Multicenter, double-blind
75. Cruciani M, de Lalla F, Mengoli C. Prophylaxis of Candida trial of a high-dose caspofungin treatment regimen versus a
infections in adult trauma and surgical intensive care patients: standard caspofungin treatment regimen for adult patients with
a systematic review and meta-analysis. Intensive Care Med. invasive candidiasis. Clin Infect Dis. 2009;48:1676-1684.
2005;31:1479-1487. 92. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus
76. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. a regimen of amphotericin B followed by fluconazole for
Fluconazole prophylaxis in critically ill surgical patients: a candidaemia in non-neutropenic patients: a randomized non-
meta-analysis. Crit Care Med. 2005;33:1928-1935. inferiority trial. Lancet. 2005;366:1435-1442.

Section05-O-ref.indd 3 1/20/2015 4:51:22 PM